التفاصيل البيبلوغرافية
| العنوان: |
The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study |
| المؤلفون: |
Tim C. de Ruijter, Kim M. Smits, Maureen J. Aarts, Irene E. G. van Hellemond, Leander Van Neste, Bart de Vries, Petronella G. M. Peer, Jürgen Veeck, Manon van Engeland, Vivianne C. G. Tjan-Heijnen |
| المصدر: |
Diagnostic and Prognostic Research, Vol 3, Iss 1, Pp 1-8 (2019) |
| بيانات النشر: |
BMC, 2019. |
| سنة النشر: |
2019 |
| المجموعة: |
LCC:Medicine (General) |
| مصطلحات موضوعية: |
Breast cancer, Predictive factors, Prognostic factors, Adjuvant treatment, Hormone receptor-positive, Endocrine treatment, Medicine (General), R5-920 |
| الوصف: |
Abstract Background The effect of extended adjuvant aromatase inhibition in hormone-positive breast cancer after sequential tamoxifen, aromatase inhibitor treatment of 5 years was recently investigated by the DATA study. This study found no statistically significant effect of prolonged aromatase therapy. However, subgroup analysis showed post hoc statistically significant benefits in certain sub-populations. The trans-DATA study is a translational sub-study aiming to identify DNA methylation markers prognostic of patient outcome. Methods Patients from the DATA study are included in the trans-DATA study. Primary breast tumour tissue will be collected, subtyped and used for DNA isolation. A genome-wide DNA methylation discovery assay will be performed on 60 patients that had a distant recurrence and 60 patients that did not have a distant recurrence using the Infinium Methylation EPIC Bead Chip platform. Differentially methylated regions of interest will be selected based on Akaike’s Information Criterion, Gene Ontology Analysis and correlation between methylation and expression levels. Selected candidate genes will subsequently be validated in the remaining patients using qMSP. Discussion The trans-DATA study uses a cohort derived from a clinical randomised trial. This study was designed to avoid common pitfalls in marker discovery studies such as selection bias, confounding and lack of reproducibility. In addition to the usual clinical risk factors, the results of this study may identify predictors of high recurrence risk in hormone receptor-positive breast cancer patients treated with sequential tamoxifen and aromatase inhibitor therapy. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2397-7523 |
| Relation: |
http://link.springer.com/article/10.1186/s41512-019-0065-6; https://doaj.org/toc/2397-7523 |
| DOI: |
10.1186/s41512-019-0065-6 |
| URL الوصول: |
https://doaj.org/article/f6e07aacda75400586e399d84923b11c |
| رقم الانضمام: |
edsdoj.f6e07aacda75400586e399d84923b11c |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder